Recce Pharmaceuticals Ltd (ASX:RCE)
Australia
· Delayed Price · Currency is AUD 0.460
-0.020 (-4.17%)
At close: Mar 6, 2026
Recce Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Other Revenue | 0.97 | 7.51 | 5.03 | 4.37 | 3.08 | 1.64 | Upgrade
|
| Revenue | 0.97 | 7.51 | 5.03 | 4.37 | 3.08 | 1.64 | Upgrade
|
| Revenue Growth (YoY) | -89.84% | 49.33% | 15.19% | 41.50% | 88.41% | 45.97% | Upgrade
|
| Cost of Revenue | 12.15 | 10.45 | 7.22 | 7.41 | 6.33 | 5.7 | Upgrade
|
| Gross Profit | -11.18 | -2.94 | -2.19 | -3.05 | -3.25 | -4.07 | Upgrade
|
| Selling, General & Admin | 8.81 | 8.36 | 7.09 | 5.75 | 3.54 | 2.29 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | 0.14 | - | Upgrade
|
| Other Operating Expenses | 6.99 | 7.41 | 7.33 | 3.53 | 2.42 | 1.63 | Upgrade
|
| Operating Expenses | 17.86 | 17.47 | 14.81 | 9.83 | 6.4 | 9.44 | Upgrade
|
| Operating Income | -29.04 | -20.41 | -17 | -12.88 | -9.65 | -13.51 | Upgrade
|
| Interest Expense | -1.36 | -1.21 | -0.84 | -0.18 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.07 | 0.11 | 0.19 | 0.07 | 0.09 | 0.11 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.13 | 0.13 | -0 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.05 | -0.05 | -0.01 | -0.01 | -0 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | -30.25 | -21.43 | -17.66 | -12.99 | -9.57 | -13.51 | Upgrade
|
| Legal Settlements | - | - | - | -0.08 | -1.42 | - | Upgrade
|
| Pretax Income | -30.25 | -21.43 | -17.66 | -13.08 | -10.99 | -13.51 | Upgrade
|
| Net Income | -30.25 | -21.43 | -17.66 | -13.08 | -10.99 | -13.51 | Upgrade
|
| Net Income to Common | -30.25 | -21.43 | -17.66 | -13.08 | -10.99 | -13.51 | Upgrade
|
| Shares Outstanding (Basic) | 267 | 237 | 177 | 174 | 174 | 155 | Upgrade
|
| Shares Outstanding (Diluted) | 267 | 237 | 177 | 174 | 174 | 155 | Upgrade
|
| Shares Change (YoY) | 36.61% | 33.81% | 1.79% | -0.09% | 12.05% | 22.17% | Upgrade
|
| EPS (Basic) | -0.11 | -0.09 | -0.10 | -0.08 | -0.06 | -0.09 | Upgrade
|
| EPS (Diluted) | -0.11 | -0.09 | -0.10 | -0.08 | -0.06 | -0.09 | Upgrade
|
| Free Cash Flow | -23.04 | -20.47 | -13.15 | -12.73 | -9.05 | -7.93 | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.09 | -0.07 | -0.07 | -0.05 | -0.05 | Upgrade
|
| Gross Margin | - | -39.12% | -43.52% | -69.83% | -105.22% | -248.40% | Upgrade
|
| Operating Margin | -2980.30% | -271.76% | -338.04% | -295.00% | -312.74% | -824.91% | Upgrade
|
| Profit Margin | -3104.24% | -285.37% | -351.24% | -299.58% | -356.12% | -825.30% | Upgrade
|
| Free Cash Flow Margin | -2364.45% | -272.59% | -261.53% | -291.53% | -293.38% | -484.42% | Upgrade
|
| EBITDA | -28.99 | -20.33 | -16.93 | -12.83 | -9.6 | -13.39 | Upgrade
|
| EBITDA Margin | - | -270.81% | - | -293.92% | - | - | Upgrade
|
| D&A For EBITDA | 0.05 | 0.07 | 0.07 | 0.05 | 0.05 | 0.12 | Upgrade
|
| EBIT | -29.04 | -20.41 | -17 | -12.88 | -9.65 | -13.51 | Upgrade
|
| EBIT Margin | - | -271.76% | - | -295.00% | - | - | Upgrade
|
| Advertising Expenses | - | 1.24 | 1.24 | 1.12 | 0.99 | 0.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.